Stocks

After too-bleak an outlook in legal weed, the firm says it can better secure shareholder value via pharmaceutical development

The methods will be available as part of third-party client services

The firm says opportunities lie in new genetics and its EU GMP-certified operations in Portugal

Each shareholder's ownership in the firm and proportional voting power remains the same

Early feedback on the firm's cannabis products has been strong

The Montreal-based producer will have access to additional cultivation space, more than doubling annual production capacity

TGOD says new acquisitions and marketing partnerships will help boost sales

Company executives say the quarter was important for securing future growth

A subsidiary of Xebra Brands has been challenging prohibition in lower courts for 3 years

The firm's new CEO looks to be off to a strong start

Terry Booth's firm says it's continuing with an 'asset light' approach

The letter has no current impact on its listing, company says

Growth was driven by medical cannabis clinic operations in Colombia and Germany, company says

Third-party cannabis delivery isn't yet allowed in the province

The firm is buying 80% of NuLeaf for US$31M

Earlier in November, the company told shareholders it wouldn't be EBITDA-positive in fiscal 2021

But other profitability metrics lagged in the quarter

The firm says it had its first EBITDA-profitable month in September

Delays to store openings and 'unforeseen' regulatory issues have caused the firm to rein in its earnings projections for the year

But net income soared due to a US$69M value gain on warrants

The firm blamed the drop in part on 'seasonal weakness'

Currently only a handful of Canadian nurseries supply genetics to hundreds of licensed pot producers

But concerns remain around its significant debt pile and an inability to pay it off

The firm upped Q3 revenue by 17% but tallied a $13.5M loss

Rose is a third-party supplier for major cannabis companies and micros in Quebec

Particularly the firm's new retail acquisition is turning a profit

The firm is projecting revenues to rise another 9% in Q4

The leading US weed firm continues to post solid growth and fundamentals

The company says a majority of new sales growth is coming from its focus on medical cannabis

Net loss ballooned 507% to US$59 million this fiscal period due to rising expenses

Company stock soared 12% on Tuesday

Around 155 employees will be impacted by the decision to shut down the facilities and centralize operations

Citizen Stash shareholders approved the deal in a special meeting Nov. 1

The Netherlands could have Europe's first adult-use cannabis market

Q2 revenue dipped 6% to $146M

The firm says it can now export biomass and flower to its international clients

The company says it will use data from its clinics in Colombia and Peru to help treat patients in the UK

HYTN's sparkling THC-infused drinks are expected to be on the shelves before the end of the year

A citrus soda and two gummy flavours, all with 10mg of THC, will be available to Canadians

The transaction is expected to close around Nov. 15